Randomized Phase Iii Trial Of Erlotinib (E) Versus Docetaxel (D) As Second- Or Third-Line Therapy In Patients With Advanced Non-Small Cell Lung Cancer (Nsclc) Who Have Wild-Type Or Mutant Epidermal Growth Factor Receptor (Egfr): Docetaxel And Erlotinib Lung Cancer Trial (Delta).

8006 Background: E and D are standard cares for previously treated patients with advanced NSCLC. Although E shows significant clinical benefits over best supportive care in the EGFR wild type tumors, it remains unknown whether E or D is more active against the disease. Methods: This is an open-label, multi-center phase III study, sponsored by the Japanese National Hospital Organization. Patients were randomized to E (150 mg, daily), or D (60 mg/m2, q3w) by the minimization method according to gender, performance status, histology, and institution. The primary endpoint was progression free survival (PFS), and secondary endpoints included overall survival (OS), response rate, safety, and analyses on EGFR wild type tumors. Eligible patients were those with pathologically proven NSCLC with stage IIIB or IV (AJCC version 6) previously treated with one or two chemotherapy regimens including at least one platinum agent, evaluable or measurable disease, and ECOG PS 0-2. Target sample size was calculated to be 280...